Company News

  • 18 October 2019

    Verona Pharma closes enrolment in Phase IIb COPD trial

    UK-based biopharmaceutical firm Verona Pharma has completed patient enrolment in a Phase IIb clinical trial of nebulised ensifentrine (RPL554) to treat moderate-to-severe chronic obstructive pulmonary disease (COPD).

Close
Close
Close

Go Top